Amyloid imaging in alzheimer's disease and other dementias

Brain Imaging and Behavior

Volumn 3, Issue 3, 2009, Pages 246-261

  Fodero Tavoletti, Michelle T ^a,b,c   Cappai, Roberto ^a,b,c   McLean, Catriona A ^d   Pike, Kerryn E ^c,e   Adlard, Paul A ^c   Cowie, Tiffany ^a   Connor, Andrea R ^a,b,c   Masters, Colin L ^c   Rowe, Christopher C ^e   Villemagne, Victor L ^a,c,e  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

A ; Alzheimer's disease; Brain imaging; Dementia; Emission tomography; PiB

Indexed keywords

3' F PIB F 18; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID P COMPONENT; APOLIPOPROTEIN E4; AV 45 F 18; BASIC FIBROBLAST GROWTH FACTOR; BAY 94 91772; BAY 94 91772 F 18; BF 227; BF 227 C 11; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CONGO RED; FDDNP F 18; FLUORESCENT DYE; FLUORODEOXYGLUCOSE F 18; I CQ I 123; IMPY I 123; PIB C 11; PRESENILIN 1; RADIOPHARMACEUTICAL AGENT; SB 13; SB 13 C 11; THIOFLAVINE; TRACER; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BRAIN ATROPHY; CAUDATE NUCLEUS; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; DEMENTIA; DENSITY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG BINDING; DRUG SELECTIVITY; EARLY DIAGNOSIS; EPISODIC MEMORY; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; GENOTYPE; GRAY MATTER; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; MEMORY DISORDER; MOLECULAR IMAGING; NERVE CELL; NERVE DEGENERATION; NEURITE; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROTOXICITY; NORMOTENSIVE HYDROCEPHALUS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBITAL CORTEX; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FOLDING; VASCULAR AMYLOIDOSIS; WHITE MATTER;

EID: 77949656112     PISSN: 19317557     EISSN: 19317565     Source Type: Journal    
DOI: 10.1007/s11682-009-9067-2     Document Type: Article

References (175)

1. Agdeppa, E. D., Kepe, V., Petri, A., Satyamurthy, N., Liu, J., Huang, S. C., et al. (2003). In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18) F]fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile. Neuroscience, 117(3), 723-730. doi: 10. 1016/S0306-4522(02)00907-7.
2. Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., et al. (2008). Frequent amyloid deposition without significant cognitive impairment among the elderly. Archives of Neurology, 65(11), 1509-1517. doi: 10. 1001/archneur. 65. 11. 1509.
3. Archer, H. A., Edison, P., Brooks, D. J., Barnes, J., Frost, C., Yeatman, T., et al. (2006). Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Annals of Neurology, 60(1), 145-147. doi: 10. 1002/ana. 20889.
4. Arnold, S. E., Han, L. Y., Clark, C. M., Grossman, M., & Trojanowski, J. Q. (2000). Quantitative neurohistological features of frontotemporal degeneration. Neurobiology of Aging, 21(6), 913-919. doi: 10. 1016/S0197-4580(00)00173-1.
5. Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992). Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42(3 Pt 1), 631-639.
6. Backman, L., Jones, S., Berger, A. K., Laukka, E. J., & Small, B. J. (2005). Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology, 19(4), 520-531. doi: 10. 1037/0894-4105. 19. 4. 520.
7. Bacskai, B. J., Hickey, G. A., Skoch, J., Kajdasz, S. T., Wang, Y., Huang, G. F., et al. (2003). Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 100(21), 12462-12467. doi: 10. 1073/pnas. 2034101100.
8. Bacskai, B. J., Frosch, M. P., Freeman, S. H., Raymond, S. B., Augustinack, J. C., Johnson, K. A., et al. (2007). Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Archives of Neurology, 64(3), 431-434. doi: 10. 1001/archneur. 64. 3. 431.
9. Barrio, J. R., Huang, S. C., Cole, G., Satyamurthy, N., Petric, A., Phelps, M. E., et al. (1999). PET imaging of tangles and plaques in Alzheimer disease with a highly lipophilic probe. Journal of Labelled Compounds & Radiopharmaceuticals, 42, S194-S195.
10. Bennett, D. A. (2000). Part I. Epidemiology and public health impact of Alzheimer's disease. Disease-a-month, 46(10), 657-665. doi: 10. 1016/S0011-5029(00)90028-2.
11. Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., et al. (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66(12), 1837-1844. doi: 10. 1212/01. wnl. 0000219668. 47116. e6.
12. Boxer, A. L., Rabinovici, G. D., Kepe, V., Goldman, J., Furst, A. J., Huang, S. C., et al. (2007). Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology, 69(3), 283-290. doi: 10. 1212/01. wnl. 0000265815. 38958. b6.
13. Braak, H., & Braak, E. (1997). Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiology of Aging, 18(4), 351-357. doi: 10. 1016/S0197-4580(97)00056-0.
14. Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., et al. (2005). Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. Journal of Neuroscience, 25(34), 7709-7717. doi: 10. 1523/JNEUROSCI. 2177-05. 2005.
15. Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain's default network: anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, 1124, 1-38. doi: 10. 1196/annals. 1440. 011.
16. Cairns, N. J., Neumann, M., Bigio, E. H., Holm, I. E., Troost, D., Hatanpaa, K. J., et al. (2007). TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. American Journal of Pathology, 171(1), 227-240. doi: 10. 2353/ajpath. 2007. 070182.
17. Cappai, R., & White, A. R. (1999). Amyloid beta. The International Journal of Biochemistry & Cell Biology, 31(9), 885-889. doi: 10. 1016/S1357-2725(99)00027-8.
18. Chou, Y. C., Teng, M. M., Guo, W. Y., Hsieh, J. C., & Wu, Y. T. (2007). Classification of hemodynamics from dynamic-susceptibility-contrast magnetic resonance (DSC-MR) brain images using noiseless independent factor analysis. Medical Image Analysis, 11(3), 242-253. doi: 10. 1016/j. media. 2007. 02. 002.
19. Clark, C. M., Davatzikos, C., Borthakur, A., Newberg, A., Leight, S., Lee, V. M., et al. (2008). Biomarkers for early detection of Alzheimer pathology. Neuro-Signals, 16(1), 11-18. doi: 10. 1159/000109754.
20. Davies, L., Wolska, B., Hilbich, C., Multhaup, G., Martins, R., Simms, G., et al. (1988). A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology, 38(11), 1688-1693.
21. de Leon, M. J., Convit, A., DeSanti, S., Bobinski, M., George, A. E., Wisniewski, H. M., et al. (1997). Contribution of structural neuroimaging to the early diagnosis of Alzheimer's disease. International Psychogeriatrics, 9(Suppl 1), 183-190. doi: 10. 1017/S1041610297004900. discussion 247-152.
22. Deshpande, A., Mina, E., Glabe, C., & Busciglio, J. (2006). Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. Journal of Neuroscience, 26(22), 6011-6018. doi: 10. 1523/JNEUROSCI. 1189-06. 2006.
23. Dickerson, B. C., Goncharova, I., Sullivan, M. P., Forchetti, C., Wilson, R. S., Bennett, D. A., et al. (2001). MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiology of Aging, 22(5), 747-754. doi: 10. 1016/S0197-4580(01)00271-8.
24. Drzezga, A., Grimmer, T., Henriksen, G., Stangier, I., Perneczky, R., Diehl-Schmid, J., et al. (2008). Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. NeuroImage, 39(2), 619-633. doi: 10. 1016/j. neuroimage. 2007. 09. 020.
25. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T., Barberger-Gateau, P., Cummings, J., et al. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology, 6(8), 734-746. doi: 10. 1016/S1474-4422(07)70178-3.
26. Eckert, A., Keil, U., Marques, C. A., Bonert, A., Frey, C., Schussel, K., et al. (2003). Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochemical Pharmacology, 66(8), 1627-1634. doi: 10. 1016/S0006-2952(03)00534-3.
27. Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., et al. (2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology, 68(7), 501-508. doi: 10. 1212/01. wnl. 0000244749. 20056. d4.
28. Edison, P., Rowe, C. C., Rinne, J. O., Ng, S., Ahmed, I., Kemppainen, N., et al. (2008). Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. Journal of Neurology, Neurosurgery and Psychiatry, 79(12), 1331-1338. doi: 10. 1136/jnnp. 2007. 127878.
29. Engler, H., Forsberg, A., Almkvist, O., Blomquist, G., Larsson, E., Savitcheva, I., et al. (2006). Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 129(Pt 11), 2856-2866. doi: 10. 1093/brain/awl178.
30. Engler, H., Santillo, A. F., Wang, S. X., Lindau, M., Savitcheva, I., Nordberg, A., et al. (2008). In vivo amyloid imaging with PET in frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 35(1), 100-106. doi: 10. 1007/s00259-007-0523-1.
31. Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S. Y., Dence, C. S., Shah, A. R., et al. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans. Annals of Neurology, 59(3), 512-519. doi: 10. 1002/ana. 20730.
32. Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007). Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology, 64(3), 343-349. doi: 10. 1001/archneur. 64. 3. noc60123.
33. Fodero-Tavoletti, M. T., Smith, D. P., McLean, C. A., Adlard, P. A., Barnham, K. J., Foster, L. E., et al. (2007). In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. Journal of Neuroscience, 27(39), 10365-10371. doi: 10. 1523/JNEUROSCI. 0630-07. 2007.
34. Fodero-Tavoletti, M. T., Rowe, C. C., McLean, C. A., Leone, L., Li, Q. X., Masters, C. L., et al. (2009). Characterization of PiB Binding to White Matter in Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine, 50(2), 198-204. doi: 10. 2967/jnumed. 2108. 057984.
35. Forman, M. S., Mufson, E. J., Leurgans, S., Pratico, D., Joyce, S., Leight, S., et al. (2007). Cortical biochemistry in MCI and Alzheimer disease: lack of correlation with clinical diagnosis. Neurology, 68(10), 757-763. doi: 10. 1212/01. wnl. 0000256373. 39415. b1.
36. Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A., et al. (2008). PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging, 29(10), 1456-1465. doi: 10. 1016/j. neurobiolaging. 2007. 03. 029.
37. Frank, R. A., Galasko, D., Hampel, H., Hardy, J., de Leon, M. J., Mehta, P. D., et al. (2003). Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging, 24(4), 521-536. doi: 10. 1016/S0197-4580(03)00002-2.
38. Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gomez-Isla, T., & Hyman, B. T. (1995). Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Annals of Neurology, 38(2), 254-259. doi: 10. 1002/ana. 410380219.
39. Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C. M., Shoji, M., & Younkin, S. G. (2000). Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochemical and Biophysical Research Communications, 276(2), 422-427. doi: 10. 1006/bbrc. 2000. 3490.
40. Ibaraki, M., Shimosegawa, E., Toyoshima, H., Ishigame, K., Ito, H., Takahashi, K., et al. (2005). Effect of regional tracer delay on CBF in healthy subjects measured with dynamic susceptibility contrast-enhanced MRI: comparison with 15O-PET. Magnetic Resonance in Medical Sciences, 4(1), 27-34. doi: 10. 2463/mrms. 4. 27.
41. Ichise, M., Golan, H., Ballinger, J. R., Vines, D., Blackman, A., & Moldofsky, H. (1997). Regional differences in technetium-99m-ECD clearance on brain SPECT in healthy subjects. Journal of Nuclear Medicine, 38(8), 1253-1260.
42. Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., et al. (2008). Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain, 131(Pt 6), 1630-1645. doi: 10. 1093/brain/awn016.
43. Jellinger, K. (1990). Morphology of Alzheimer disease and related disorders. In K. Maurer, P. Riederer & H. Beckmann (Eds.), Alzheimer disease: Epidemiology, neuropathology, neurochemistry, and clinics, pp. 61-77. Berlin: Springer-Verlag.
44. Jellinger, K. A., & Bancher, C. (1998). Neuropathology of Alzheimer's disease: a critical update. Journal of Neural Transmission. Supplementum, 54, 77-95.
45. Joachim, C. L., Morris, J. H., & Selkoe, D. J. (1989). Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. American Journal of Pathology, 135(2), 309-319.
46. Johansson, A., Savitcheva, I., Forsberg, A., Engler, H., Langstrom, B., Nordberg, A., et al. (2008). [(11) C]-PIB imaging in patients with Parkinson's disease: preliminary results. Parkinsonism & Related Disorders, 14(4), 345-347. doi: 10. 1016/j. parkreldis. 2007. 07. 010.
47. Johnson, N., Davis, T., & Bosanquet, N. (2000). The epidemic of Alzheimer's disease. How can we manage the costs? PharmacoEconomics, 18(3), 215-223. doi: 10. 2165/00019053-200018030-00002.
48. Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., et al. (2007). Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Annals of Neurology, 62(3), 229-234. doi: 10. 1002/ana. 21164.
49. Kemppainen, N. M., Aalto, S., Wilson, I. A., Nagren, K., Helin, S., Bruck, A., et al. (2007). PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 68(19), 1603-1606. doi: 10. 1212/01. wnl. 0000260969. 94695. 56.
50. Kemppainen, N. M., Aalto, S., Karrasch, M., Nagren, K., Savisto, N., Oikonen, V., et al. (2008). Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Annals of Neurology, 63(1), 112-118. doi: 10. 1002/ana. 21212.
51. Killiany, R. J., Gomez-Isla, T., Moss, M., Kikinis, R., Sandor, T., Jolesz, F., et al. (2000). Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Annals of Neurology, 47(4), 430-439. doi: 10. 1002/1531-8249(200004)47: 4< 430:: AID-ANA5> 3. 0. CO; 2-I.
52. Klunk, W. E., Wang, Y., Huang, G. F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001a). Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sciences, 69(13), 1471-1484. doi: 10. 1016/S0024-3205(01)01232-2.
53. Klunk, W. E., Wang, Y., Huang, G. F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001b). Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sciences, 69(13), 1471-1484. doi: 10. 1016/S0024-3205(01)01232-2.
54. Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., et al. (2002). Imaging Aß plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. Journal of Neuropathology and Experimental Neurology, 61(9), 797-805.
55. Klunk, W. E., Wang, Y., Huang, G. F., Debnath, M. L., Holt, D. P., Shao, L., et al. (2003a). The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. Journal of Neuroscience, 23(6), 2086-2092.
56. Klunk, W. E., Wang, Y., Huang, G. F., Debnath, M. L., Holt, D. P., Shao, L., et al. (2003b). The binding of 2-(4′-methylaminophenyl) benzothiazole to postmortem brain homogenates is dominated by the amyloid component. Journal of Neuroscience, 23(6), 2086-2092.
57. Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 55(3), 306-319. doi: 10. 1002/ana. 20009.
58. Klunk, W. E., Lopresti, B. J., Ikonomovic, M. D., Lefterov, I. M., Koldamova, R. P., Abrahamson, E. E., et al. (2005). Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. Journal of Neuroscience, 25(46), 10598-10606. doi: 10. 1523/JNEUROSCI. 2990-05. 2005.
59. Klunk, W. E., Price, J. C., Mathis, C. A., Tsopelas, N. D., Lopresti, B. J., Ziolko, S. K., et al. (2007). Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. Journal of Neuroscience, 27(23), 6174-6184. doi: 10. 1523/JNEUROSCI. 0730-07. 2007.
60. Kudo, Y. (2006). Development of amyloid imaging PET probes for an early diagnosis of Alzheimer's disease. Minimally Invasive Therapy & Allied Technologies, 15(4), 209-213. doi: 10. 1080/13645700600836000.
61. Kudo, Y., Okamura, N., Furumoto, S., Tashiro, M., Furukawa, K., Maruyama, M., et al. (2007). 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6- (2-[Fluoro]Ethoxy) Benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. Journal of Nuclear Medicine, 48(4), 553-561. doi: 10. 2967/jnumed. 106. 037556.
62. Kung, M. P., Skovronsky, D. M., Hou, C., Zhuang, Z. P., Gur, T. L., Zhang, B., et al. (2003). Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients. Journal of Molecular Neuroscience, 20(1), 15-24. doi: 10. 1385/JMN: 20: 1: 15.
63. Kung, M. P., Hou, C., Zhuang, Z. P., Skovronsky, D., & Kung, H. F. (2004). Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease. Brain Research, 1025(1-2), 98-105. doi: 10. 1016/j. brainres. 2004. 08. 004.
64. Kurihara, A., & Pardridge, W. M. (2000). Abeta(1-40) peptide radiopharmaceuticals for brain amyloid imaging: (111) In chelation, conjugation to poly(ethylene glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain sections. Bioconjugate Chemistry, 11(3), 380-386. doi: 10. 1021/bc9901393.
65. Kwong, L. K., Uryu, K., Trojanowski, J. Q., & Lee, V. M. (2008). TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neuro-Signals, 16(1), 41-51. doi: 10. 1159/000109758.
66. Lee, V. M. (2002). Related Amyloid binding ligands as Alzheimer's disease therapies. Neurobiology of Aging, 23(6), 1039-1042. doi: 10. 1016/S0197-4580(02)00121-5.
67. Leinonen, V., Alafuzoff, I., Aalto, S., Suotunen, T., Savolainen, S., Nagren, K., et al. (2008). Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Archives of Neurology, 65(10), 1304-1309. doi: 10. 1001/archneur. 65. 10. noc80013.
68. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J. B., et al. (2007). Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxidants & Redox Signalling, 9(10), 1659-1675. doi: 10. 1089/ars. 2007. 1763.
69. LeVine, H,. I. I. I. (1999). Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods in Enzymology, 309, 274-284. doi: 10. 1016/S0076-6879(99)09020-5.
70. Levine, H., III, & Walker, L. C. (2008). Molecular polymorphism of Abeta in Alzheimer's disease. Neurobiol Aging.
71. Li, Y., Rinne, J. O., Mosconi, L., Pirraglia, E., Rusinek, H., Desanti, S., et al. (2008). Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging.
72. Link, C. D., Johnson, C. J., Fonte, V., Paupard, M., Hall, D. H., Styren, S., et al. (2001). Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiology of Aging, 22(2), 217-226. doi: 10. 1016/S0197-4580(00)00237-2.
73. Lockhart, A., Ye, L., Judd, D. B., Merritt, A. T., Lowe, P. N., Morgenstern, J. L., et al. (2005). Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. Journal of Biological Chemistry, 280(9), 7677-7684. doi: 10. 1074/jbc. M412056200.
74. Lockhart, A., Lamb, J. R., Osredkar, T., Sue, L. I., Joyce, J. N., Ye, L., et al. (2007). PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain, 130(Pt 10), 2607-2615. doi: 10. 1093/brain/awm191.
75. Logan, J., Fowler, J. S., Volkow, N. D., Wang, G. J., Ding, Y. S., & Alexoff, D. L. (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of Cerebral Blood Flow and Metabolism, 16, 834-840. doi: 10. 1097/00004647-199609000-00008.
76. Lopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., et al. (2005). Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. Journal of Nuclear Medicine, 46(12), 1959-1972.
77. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. American Journal of Pathology, 155(3), 853-862.
78. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. Journal of Neuroscience, 27(41), 10957-10968. doi: 10. 1523/JNEUROSCI. 0673-07. 2007.
79. Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., et al. (2008). [11C]PIB binding in Parkinson's disease dementia. NeuroImage, 39(3), 1027-1033. doi: 10. 1016/j. neuroimage. 2007. 09. 072.
80. Maezawa, I., Hong, H. S., Liu, R., Wu, C. Y., Cheng, R. H., Kung, M. P., et al. (2008). Congo red and thioflavin-T analogs detect Abeta oligomers. Journal of Neurochemistry, 104(2), 457-468.
81. Majocha, R. E., Reno, J. M., Friedland, R. P., van Haight, C., Lyle, L. R., & Marotta, C. A. (1992). Development of a monoclonal antibody specific for ß/A4 amyloid in Alzheimer's disease brain for application to in vivo imaging of amyloid angiopathy. Journal of Nuclear Medicine, 33(12), 2184-2189.
82. Marshall, J. R., Stimson, E. R., Ghilardi, J. R., Vinters, H. V., Mantyh, P. W., & Maggio, J. E. (2002). Noninvasive imaging of peripherally injected Alzheimer's disease type synthetic A beta amyloid in vivo. Bioconjugate Chemistry, 13(2), 276-284. doi: 10. 1021/bc010066z.
83. Martins, I. J., Hone, E., Foster, J. K., Sunram-Lea, S. I., Gnjec, A., Fuller, S. J., et al. (2006). Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Molecular Psychiatry, 11(8), 721-736. doi: 10. 1038/sj. mp. 4001854.
84. Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., et al. (2001). Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 98(21), 12245-12250. doi: 10. 1073/pnas. 211412398.
85. Masters, C. L. (2005). Neuropathology of Alzheimer's Disease. Dementia (3rd Edition). A. Burns, J. O'Brien and D. Ames. London, Hodder Arnold: 393-407.
86. Masters, C. L., & Beyreuther, K. (2005). The neuropathology of Alzheimer's disease in the year 2005. In M. F. Beal, A. E. Lang & A. C. Ludolph (Eds.), Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, pp. 433-440. Cambridge: Cambridge University Press.
87. Masters, C. L., & Beyreuther, K. (2006). Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain, 129(Pt 11), 2823-2839. doi: 10. 1093/brain/awl251.
88. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences of the United States of America, 82(12), 4245-4249. doi: 10. 1073/pnas. 82. 12. 4245.
89. Masters, C. L., Cappai, R., Barnham, K. J., & Villemagne, V. L. (2006). Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry, 97(6), 1700-1725. doi: 10. 1111/j. 1471-4159. 2006. 03989. x.
90. Mathis, C. A., Holt, D. P., Wang, Y., Huang, G. F., Debnath, M. L., & Klunk, W. E. (2001). Lipophilic 11C-labelled thioflavin-T analogues for imaging amyloid plaques in Alzheimer's disease. Journal of Labelled Compounds & Radiopharmaceuticals, 44(Suppl 1), S26-S28.
91. Mathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., et al. (2002a). A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic & Medicinal Chemistry Letters, 12(3), 295-298. doi: 10. 1016/S0960-894X(01)00734-X.
92. Mathis, C. A., Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Hyman, B. T., et al. (2002b). A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorganic & Medicinal Chemistry Letters, 12(3), 295-298. doi: 10. 1016/S0960-894X(01)00734-X.
93. Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., & Klunk, W. E. (2003). Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. Journal of Medicinal Chemistry, 46(13), 2740-2754. doi: 10. 1021/jm030026b.
94. Mathis, C. A., Klunk, W. E., Price, J. C., & DeKosky, S. T. (2005). Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Archives of Neurology, 62(2), 196-200. doi: 10. 1001/archneur. 62. 2. 196.
95. Mathis, C. A., Lopresti, B. J., & Klunk, W. E. (2007a). Impact of amyloid imaging on drug development in Alzheimer's disease. Nuclear Medicine and Biology, 34(7), 809-822. doi: 10. 1016/j. nucmedbio. 2007. 06. 015.
96. Mathis, C. A., Lopresti, B. J., Mason, N., Price, J., Flatt, N., Bi, W., et al. (2007b). Comparison of the amyloid imaging agents [F-18]3'-F-PIB and [C-11]PIB in Alzheimer's disease and control subjects. Journal of Nuclear Medicine, 48(Suppl. 2), 56P.
97. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology, 34, 939-944.
98. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., et al. (1999). Soluble pool of Aß amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annals of Neurology, 46(6), 860-866. doi: 10. 1002/1531-8249(199912)46: 6< 860:: AID-ANA8> 3. 0. CO; 2-M.
99. McLean, C. A., Beyreuther, K., & Masters, C. L. (2001). Amyloid Abeta levels in Alzheimer's disease - A diagnostic tool and the key to understanding the natural history of Abeta? Journal of Alzheimer's Disease, 3(3), 305-312.
100. Mega, M. S., Dinov, I. D., Porter, V., Chow, G., Reback, E., Davoodi, P., et al. (2005). Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Archives of Neurology, 62(5), 721-728. doi: 10. 1001/archneur. 62. 5. 721.
101. Michaelis, M. L., Dobrowsky, R. T., & Li, G. (2002). Tau neurofibrillary pathology and microtubule stability. Journal of Molecular Neuroscience, 19(3), 289-293. doi: 10. 1385/JMN: 19: 3: 289.
102. Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., et al. (2006). [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology, 67(3), 446-452. doi: 10. 1212/01. wnl. 0000228230. 26044. a4.
103. Morris, J. C., & Price, A. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience, 17(2), 101-118. doi: 10. 1385/JMN: 17: 2: 101.
104. Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., et al. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology, 58(3), 397-405. doi: 10. 1001/archneur. 58. 3. 397.
105. Mortimer, J. A. (1997). Brain reserve and the clinical expression of Alzheimer's disease. Geriatrics, 52(Suppl 2), S50-S53.
106. Naslund, J., Haroutunian, V., Mohs, R., Davis, K. L., Davies, P., Greengard, P., et al. (2000). Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. Journal of the American Medical Association, 283(12), 1571-1577. doi: 10. 1001/jama. 283. 12. 1571.
107. Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130-133. doi: 10. 1126/science. 1134108.
108. Newberg, A. B., Wintering, N. A., Plossl, K., Hochold, J., Stabin, M. G., Watson, M., et al. (2006). Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. Journal of Nuclear Medicine, 47(5), 748-754.
109. Ng, S., Villemagne, V. L., Berlangieri, S., Lee, S. T., Cherk, M., Gong, S. J., et al. (2007a). Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. Journal of Nuclear Medicine, 48(4), 547-552. doi: 10. 2967/jnumed. 106. 037762.
110. Ng, S. Y., Villemagne, V. L., Masters, C. L., & Rowe, C. C. (2007b). Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B. Archives of Neurology, 64(8), 1140-1144. doi: 10. 1001/archneur. 64. 8. 1140.
111. Nordberg, A. (2007). Amyloid imaging in Alzheimer's disease. Current Opinion in Neurology, 20(4), 398-402. doi: 10. 1097/WCO. 0b013e3281a47744.
112. Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., et al. (2005). Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. Journal of Neuroscience, 25(47), 10857-10862. doi: 10. 1523/JNEUROSCI. 1738-05. 2005.
113. Ono, M., Wilson, A., Nobrega, J., Westaway, D., Verhoeff, P., Zhuang, Z. P., et al. (2003). 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nuclear Medicine and Biology, 30(6), 565-571. doi: 10. 1016/S0969-8051(03)00049-0.
114. Opazo, C., Luza, S., Villemagne, V. L., Volitakis, I., Rowe, C., Barnham, K. J., et al. (2006). Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell, 5(1), 69-79. doi: 10. 1111/j. 1474-9726. 2006. 00196. x.
115. Petersen, R. C. (2000a). Aging, mild cognitive impairment, and Alzheimer's disease. Neurologic Clinics, 18(4), 789-806. doi: 10. 1016/S0733-8619(05)70226-7.
116. Petersen, R. C. (2000b). Mild cognitive impairment: transition between aging and Alzheimer's disease. Neurologia (Barcelona, Spain), 15(3), 93-101.
117. Petersen, R. C. (2007). Mild cognitive impairment: current research and clinical implications. Seminars in Neurology, 27(1), 22-31. doi: 10. 1055/s-2006-956752.
118. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology, 56(3), 303-308. doi: 10. 1001/archneur. 56. 3. 303.
119. Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001). Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 56(9), 1133-1142.
120. Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007). Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 130(Pt 11), 2837-2844. doi: 10. 1093/brain/awm238.
121. Poduslo, J. F., Ramakrishnan, M., Holasek, S. S., Ramirez-Alvarado, M., Kandimalla, K. K., Gilles, E. J., et al. (2007). In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. Journal of Neurochemistry, 102(2), 420-433. doi: 10. 1111/j. 1471-4159. 2007. 04591. x.
122. Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and preclinical Alzheimer's disease. Annals of Neurology, 45(3), 358-368. doi: 10. 1002/1531-8249(199903)45: 3< 358:: AID-ANA12> 3. 0. CO; 2-X.
123. Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., et al. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism, 25(11), 1528-1547. doi: 10. 1038/sj. jcbfm. 9600146.
124. Rabinovici, G. D., Furst, A. J., O'Neil, J. P., Racine, C. A., Mormino, E. C., Baker, S. L., et al. (2007). 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology, 68(15), 1205-1212. doi: 10. 1212/01. wnl. 0000259035. 98480. ed.
125. Resende, R., Pereira, C., Agostinho, P., Vieira, A. P., Malva, J. O., & Oliveira, C. R. (2007). Susceptibility of hippocampal neurons to Abeta peptide toxicity is associated with perturbation of Ca2 + homeostasis. Brain Research, 1143, 11-21. doi: 10. 1016/j. brainres. 2007. 01. 071.
126. Ritchie, K., & Dupuy, A. M. (1999). The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective. International Journal of Geriatric Psychiatry, 14(9), 695-700. doi: 10. 1002/(SICI)1099-1166(199909)14: 9< 695:: AID-GPS19> 3. 0. CO; 2-R.
127. Roder, S., Danober, L., Pozza, M. F., Lingenhoehl, K., Wiederhold, K. H., & Olpe, H. R. (2003). Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience, 120(3), 705-720. doi: 10. 1016/S0306-4522(03)00381-6.
128. Roe, C. M., Mintun, M. A., D'Angelo, G., Xiong, C., Grant, E. A., & Morris, J. C. (2008). Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Archives of Neurology, 65(11), 1467-1471. doi: 10. 1001/archneur. 65. 11. 1467.
129. Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., et al. (2007). Imaging beta-amyloid burden in aging and dementia. Neurology, 68(20), 1718-1725. doi: 10. 1212/01. wnl. 0000261919. 22630. ea.
130. Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., et al. (2008). Imaging of amyloid beta in Alzheimer's disease with (18) F-BAY94-9172, a novel PET tracer: proof of mechanism. The Lancet Neurology, 7(2), 129-135. doi: 10. 1016/S1474-4422(08)70001-2.
131. Sair, H. I., Doraiswamy, P. M., & Petrella, J. R. (2004). In vivo amyloid imaging in Alzheimer's disease. Neuroradiology, 46(2), 93-104. doi: 10. 1007/s00234-003-1034-9.
132. Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G., et al. (2006). On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry, 45(41), 12393-12399. doi: 10. 1021/bi0612667.
133. Schneider, J., Murray, J., Banerjee, S., & Mann, A. (1999). EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I-Factors associated with carer burden. International Journal of Geriatric Psychiatry, 14(8), 651-661. doi: 10. 1002/(SICI)1099-1166(199908)14: 8< 651:: AID-GPS992> 3. 0. CO; 2-B.
134. Selkoe, D. J. (2000). Imaging Alzheimer's amyloid. Nature Biotechnology, 18(8), 823-824. doi: 10. 1038/78422.
135. Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science, 298(5594), 789-791. doi: 10. 1126/science. 1074069.
136. Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M., & Trojanowski, J. Q. (2007). Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nature Reviews. Drug Discovery, 6(4), 295-303. doi: 10. 1038/nrd2176.
137. Shi, J., Perry, G., Berridge, M. S., Aliev, G., Siedlak, S. L., Smith, M. A., et al. (2002). Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. Journal of Nuclear Medicine, 43(8), 1044-1051.
138. Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., et al. (2002a). Localisation of neurofibrillary tangles and ß-amyloid plaques in the brains of living patients with Alzheimer's disease. The American Journal of Geriatric Psychiatry, 10(1), 24-35.
139. Shoghi-Jadid, K., Small, G. W., Agdeppa, E. D., Kepe, V., Ercoli, L. M., Siddarth, P., et al. (2002b). Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. The American Journal of Geriatric Psychiatry, 10(1), 24-35.
140. Silverman, D. H., & Phelps, M. E. (2001). Application of positron emission tomography for evaluation of metabolism and blood flow in human brain: normal development, aging, dementia, and stroke. Molecular Genetics and Metabolism, 74(1-2), 128-138. doi: 10. 1006/mgme. 2001. 3236.
141. Small, G. W., Agdeppa, E. D., Kepe, V., Satyamurthy, N., Huang, S. C., & Barrio, J. R. (2002). In vivo brain imaging of tangle burden in humans. Journal of Molecular Neuroscience, 19(3), 323-327. doi: 10. 1385/JMN: 19: 3: 321.
142. Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., et al. (2006). PET of brain amyloid and tau in mild cognitive impairment. New England Journal of Medicine, 355(25), 2652-2663. doi: 10. 1056/NEJMoa054625.
143. Small, B. J., Gagnon, E., & Robinson, B. (2007). Early identification of cognitive deficits: preclinical Alzheimer's disease and mild cognitive impairment. Geriatrics, 62(4), 19-23.
144. Stern, Y. (2002). What is cognitive reserve? Theory and research application of the reserve concept. Journal of the International Neuropsychological Society, 8(3), 448-460. doi: 10. 1017/S1355617702813248.
145. Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., et al. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of America, 90(5), 1977-1981. doi: 10. 1073/pnas. 90. 5. 1977.
146. Suo, Z., Wu, M., Citron, B. A., Wong, G. T., & Festoff, B. W. (2004). Abnormality of G-protein-coupled receptor kinases at prodromal and early stages of Alzheimer's disease: an association with early beta-amyloid accumulation. Journal of Neuroscience, 24(13), 3444-3452. doi: 10. 1523/JNEUROSCI. 4856-03. 2004.
147. Thal, D. R., Rub, U., Orantes, M., & Braak, H. (2002). Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology, 58, 1791-1800.
148. Thal, D. R., Del Tredici, K., & Braak, H. (2004). Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004(23): pe26.
149. Tolboom, N., Yaqub, M., Lubberink, M., Kloet, R. W., Boellaard, R., Windhorst, B., et al. (2006). Test-retest variability of [11C]PIB studies in healthy subjects and AD patients. NeuroImage, 21(Suppl. 2), T100. doi: 10. 1016/j. neuroimage. 2006. 04. 087.
150. Tomiyama, T., Nagata, T., Shimada, H., Teraoka, R., Fukushima, A., Kanemitsu, H., et al. (2008). A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Annals of Neurology, 63(3), 377-387. doi: 10. 1002/ana. 21321.
151. Toyama, H., Ye, D., Ichise, M., Liow, J. S., Cai, L., Jacobowitz, D., et al. (2005). PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging, 32(5), 593-600.
152. Trojanowski, J. Q. (2002). Emerging Alzheimer's disease therapies: focusing on the future. Neurobiology of Aging, 23(6), 985-990.
153. Verhoeff, N. P., Wilson, A. A., Takeshita, S., Trop, L., Hussey, D., Singh, K., et al. (2004). In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. The American Journal of Geriatric Psychiatry, 12(6), 584-595.
154. Villemagne, V. L., Rowe, C. C., Macfarlane, S., Novakovic, K. E., & Masters, C. L. (2005). Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. Journal of Clinical Neuroscience, 12(3), 221-230. doi: 10. 1016/j. jocn. 2004. 03. 011.
155. Villemagne, V. L., Cappai, R., Barnham, K. J., Cherny, R., Opazo, C., Novakovic, K. E., et al. (2006a). The Abeta centric pathway of Alzheimer's disease. In C. J. Barrow & B. J. Small (Eds.), Abeta Peptide and Alzheimer's Disease, pp. 5-32. London: Springer-Verlag.
156. Villemagne, V. L., Ng, S., Cappai, R., Barnham, K. J., Fodero-Tavoletti, M. T., Rowe, C. C., et al. (2006b). La Lunga Attesa: towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. The Neuroradiology Journal, 19, 51-75.
157. Villemagne, V. L., Ataka, S., Brooks, W., Wada, Y., Jones, G., Watanabe, Y., et al. (2008a). Pattern of Abeta deposition in familial Alzheimer's disease is irrespective of mutation type or cognitive status. Journal of Nuclear Medicine, 49, 216P. doi: 10. 2967/jnumed. 107. 045484. abstract.
158. Villemagne, V. L., Fodero-Tavoletti, M. T., Pike, K. E., Cappai, R., Masters, C. L., & Rowe, C. C. (2008b). The ART of Loss: abeta imaging in the evaluation of Alzheimer's disease and other dementias. Molecular Neurobiology, 38(1), 1-15. doi: 10. 1007/s12035-008-8019-y.
159. Villemagne, V. L., Pike, K. E., Ackermann, U., Jones, G., Ames, D., Ellis, K., et al. (2008c). A longitudinal study of beta-amyloid deposition with 11C-PIB-PET. Journal of Nuclear Medicine, 49, 35P. abstract.
160. Villemagne, V. L., Pike, K. E., Darby, D., Maruff, P., Savage, G., Ng, S., et al. (2008d). Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, 46(6), 1688-1697. doi: 10. 1016/j. neuropsychologia. 2008. 02. 008.
161. Villemagne, V. L., Pike, K. E., Fodero-Tavoletti, M. T., Jones, G., McLean, C., Hinton, F., et al. (2008e). Age dependent prevalence of beta-amyloid positive 11C-PIB PET in healthy elderly subjects parallels neuropathology findings. Journal of Nuclear Medicine, 49, 34P. abstract.
162. Walker, L. C., Price, D. L., Voytko, M. L., & Schenk, D. B. (1994). Labelling of cerebral amyloid in vivo with a monoclonal antibody. Journal of Neuropathology and Experimental Neurology, 53(4), 377-383. doi: 10. 1097/00005072-199407000-00009.
163. Walker, L. C., Rosen, R. F., & Levine, H,. I. I. I. (2008). Diversity of Abeta deposits in the aged brain: a window on molecular heterogeneity? Romanian Journal of Morphology and Embryology, 49(1), 5-11.
164. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416(6880), 535-539. doi: 10. 1038/416535a.
165. Walsh, D. M., Klyubin, I., Shankar, G. M., Townsend, M., Fadeeva, J. V., Betts, V., et al. (2005). The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochemical Society Transactions, 33(Pt 5), 1087-1090. doi: 10. 1042/BST20051087.
166. Wang, J., Dickson, D. W., Trojanowski, J. Q., & Lee, V. M. (1999). The levels of soluble versus insoluble brain Aß distinguish Alzheimer's disease from normal and pathologic aging. Experimental Neurology, 158(2), 328-337. doi: 10. 1006/exnr. 1999. 7085.
167. Wermke, M., Sorg, C., Wohlschlager, A. M., & Drzezga, A. (2008). A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 35(Suppl 1), S12-S24. doi: 10. 1007/s00259-007-0698-5.
168. Whyte, S., Wilson, N., Currie, J., Maruff, P., Malone, V., Shafiq-Antonacci, R., et al. (1997). Collection and normal levels of the amyloid precursor protein in plasma. Annals of Neurology, 41(1), 121-124. doi: 10. 1002/ana. 410410122.
169. Wong, D. F., Rosenberg, P., Zhou, Y., Kumar, A., Ravert, H., Brasic, J., et al. (2008). In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand [F-18]AV-45. Journal of Nuclear Medicine, 49, 214P. doi: 10. 2967/jnumed. 108. 052597. abstract.
170. Xu, Y., Jack, C. R,. Jr, O'Brien, P. C., Kokmen, E., Smith, G. E., Ivnik, R. J., et al. (2000). Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology, 54(9), 1760-1767.
171. Ye, L., Morgenstern, J. L., Gee, A. D., Hong, G., Brown, J., & Lockhart, A. (2005). Delineation of positron emission tomography imaging agent binding sites on beta-amyloid peptide fibrils. Journal of Biological Chemistry, 280(25), 23599-23604. doi: 10. 1074/jbc. M501285200.
172. Ye, L., Velasco, A., Fraser, G., Beach, T. G., Sue, L., Osredkar, T., et al. (2008). In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. Journal of Neurochemistry, 105(4), 1428-1437. doi: 10. 1111/j. 1471-4159. 2008. 05245. x.
173. Yee, S., Mathis, C., Klunk, W., Weissfeld, L., Lopresti, B., Bi, W., et al. (2007). Optimal time window for standardized uptake ratio as a simplified measure of PIB retension. Journal of Nuclear Medicine, 48, 404P.
174. Zetterberg, H., & Blennow, K. (2006). Plasma Abeta in Alzheimer's disease-up or down? The Lancet Neurology, 5(8), 638-639. doi: 10. 1016/S1474-4422(06)70503-8.
175. Zhang, W., Oya, S., Kung, M. P., Hou, C., Maier, D. L., & Kung, H. F. (2005). F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Abeta aggregates in the brain. Nuclear Medicine and Biology, 32(8), 799-809. doi: 10. 1016/j. nucmedbio. 2005. 06. 001.